TY - JOUR
T1 - Management of patients with multidrugresistant/ extensively drug-resistant tuberculosis in Europe
T2 - A TBNET consensus statement
AU - Lange, Christoph
AU - Abubakar, Ibrahim
AU - Alffenaar, Jan Willem C
AU - Bothamley, Graham
AU - Caminero, Jose A.
AU - Carvalho, Anna Cristina C
AU - Chang, Kwok Chiu
AU - Codecasa, Luigi
AU - Correia, Ana
AU - Crudu, Valeriu
AU - Davies, Peter
AU - Dedicoat, Martin
AU - Drobniewski, Francis
AU - Duarte, Raquel
AU - Ehlers, Cordula
AU - Erkens, Connie
AU - Goletti, Delia
AU - Günther, Gunar
AU - Ibraim, Elmira
AU - Kampmann, Beate
AU - Kuksa, Liga
AU - De Lange, Wiel
AU - Van Leth, Frank
AU - Van Lunzen, Jan
AU - Matteelli, Alberto
AU - Menzies, Dick
AU - Monedero, Ignacio
AU - Richter, Elvira
AU - Rüsch-Gerdes, Sabine
AU - Sandgren, Andreas
AU - Scardigli, Anna
AU - Skrahina, Alena
AU - Tortoli, Enrico
AU - Volchenkov, Grigory
AU - Wagner, Dirk
AU - Van Der Werf, Marieke J.
AU - Williams, Bhanu
AU - Yew, Wing Wai
AU - Zellweger, Jean Pierre
AU - Cirillo, Daniela Maria
PY - 2014/7/1
Y1 - 2014/7/1
N2 - The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) substantially challenges TB control, especially in the European Region of the World Health Organization, where the highest prevalence of MDR/XDR cases is reported. The current management of patients with MDR/XDR-TB is extremely complex for medical, social and public health systems. The treatment with currently available anti-TB therapies to achieve relapse-free cure is long and undermined by a high frequency of adverse drug events, suboptimal treatment adherence, high costs and low treatment success rates. Availability of optimal management for patients with MDR/XDR-TB is limited even in the European Region. In the absence of a preventive vaccine, more effective diagnostic tools and novel therapeutic interventions the control of MDR/XDR-TB will be extremely difficult. Despite recent scientific advances in MDR/XDR-TB care, decisions for the management of patients with MDR/XDR-TB and their contacts often rely on expert opinions, rather than on clinical evidence. This document summarises the current knowledge on the prevention, diagnosis and treatment of adults and children with MDR/XDR-TB and their contacts, and provides expert consensus recommendations on questions where scientific evidence is still lacking.
AB - The emergence of multidrug-resistant (MDR) and extensively drug-resistant (XDR) tuberculosis (TB) substantially challenges TB control, especially in the European Region of the World Health Organization, where the highest prevalence of MDR/XDR cases is reported. The current management of patients with MDR/XDR-TB is extremely complex for medical, social and public health systems. The treatment with currently available anti-TB therapies to achieve relapse-free cure is long and undermined by a high frequency of adverse drug events, suboptimal treatment adherence, high costs and low treatment success rates. Availability of optimal management for patients with MDR/XDR-TB is limited even in the European Region. In the absence of a preventive vaccine, more effective diagnostic tools and novel therapeutic interventions the control of MDR/XDR-TB will be extremely difficult. Despite recent scientific advances in MDR/XDR-TB care, decisions for the management of patients with MDR/XDR-TB and their contacts often rely on expert opinions, rather than on clinical evidence. This document summarises the current knowledge on the prevention, diagnosis and treatment of adults and children with MDR/XDR-TB and their contacts, and provides expert consensus recommendations on questions where scientific evidence is still lacking.
UR - http://www.scopus.com/inward/record.url?scp=84902185616&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84902185616&partnerID=8YFLogxK
U2 - 10.1183/09031936.00188313
DO - 10.1183/09031936.00188313
M3 - Article
C2 - 24659544
AN - SCOPUS:84902185616
VL - 44
SP - 23
EP - 63
JO - European Journal of Respiratory Diseases
JF - European Journal of Respiratory Diseases
SN - 0903-1936
IS - 1
ER -